{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:04:47Z","timestamp":1789743887680,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bulcan.2026.05.006","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:35:50Z","timestamp":1784806550000},"page":"1140-1147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of bevacizumab to treat glioblastoma in France: Regional practices in PACA and Corsica show a real therapeutic need"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-5179","authenticated-orcid":false,"given":"Gwendoline","family":"Felker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Rebroin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davy","family":"Beauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.05.006_bib0235","unstructured":"Sant\u00e9 publique France. Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018\u00a0\u2013\u00a0tumeurs solides\u00a0: \u00e9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim [Internet]. 2023 [cit\u00e9 10 juillet 2023]. Disponible sur\u00a0: https:\/\/www.santepubliquefrance.fr\/."},{"key":"10.1016\/j.bulcan.2026.05.006_bib0240","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit\u00a0\u2013\u00a0TEMOZOLOMIDE [Internet]. 2023 [cit\u00e9 10 juillet 2023]. Disponible sur\u00a0: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0220992.htm."},{"key":"10.1016\/j.bulcan.2026.05.006_bib0245","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit\u00a0\u2013\u00a0GLIADEL [Internet]. 2023 [cit\u00e9 26 juillet 2023]. Disponible sur\u00a0: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0267403.htm."},{"issue":"10","key":"10.1016\/j.bulcan.2026.05.006_bib0250","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0255","unstructured":"anocef_referentiel_glioblastome_2025.pdf [Internet]. [cit\u00e9 27 janvier 2026]. Disponible sur\u00a0: https:\/\/www.onco-hdf.fr\/app\/uploads\/2025\/07\/anocef_referentiel_glioblastome_2025.pdf."},{"issue":"23","key":"10.1016\/j.bulcan.2026.05.006_bib0260","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide versus maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0265","unstructured":"EMA\u00a0\u2013\u00a0refusal assessment report for avastin [Internet]. [cit\u00e9 10 juillet 2023]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/avastin-h-c-582-ii-0028-epar-refusal-assessment-report-variation_en.pdf."},{"key":"10.1016\/j.bulcan.2026.05.006_bib0270","unstructured":"Liste des m\u00e9dicaments essentiels [Internet]. Feuille de route p\u00e9nuries\u00a0\u2013\u00a0Liste des m\u00e9dicaments essentiels. 2023 [cit\u00e9 10 juillet 2023]. Disponible sur\u00a0: https:\/\/sante.gouv.fr\/."},{"issue":"11","key":"10.1016\/j.bulcan.2026.05.006_bib0275","first-page":"CD008218","article-title":"Anti-angiogenic therapy for high-grade glioma","volume":"11","author":"Ameratunga","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0280","unstructured":"ATIH\u00a0: Agence technique de l\u2019information sur l\u2019hospitalisation [Internet]. 2024 [cit\u00e9 18 janvier 2024]. Disponible sur\u00a0: https:\/\/www.atih.sante.fr\/."},{"key":"10.1016\/j.bulcan.2026.05.006_bib0285","unstructured":"R\u00e9f\u00e9rentiel des indications des sp\u00e9cialit\u00e9s pharmaceutiques inscrites sur la liste en sus [Internet]. Minist\u00e8re de la Sant\u00e9 et de la Pr\u00e9vention. 2023 [cit\u00e9 10 juillet 2023]. Disponible sur\u00a0: https:\/\/sante.gouv.fr\/soins-et-maladies\/medicaments\/professionnels-de-sante\/autorisation-de-mise-sur-le-marche\/la-liste-en-sus\/article\/referentiel-des-indications-des-specialites-pharmaceutiques-inscrites-sur-la."},{"issue":"8","key":"10.1016\/j.bulcan.2026.05.006_bib0290","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0295","unstructured":"Estimation de la population au 1er\u00a0janvier 2023 | Insee [Internet]. [cit\u00e9 18 juillet 2023]. Disponible sur\u00a0: https:\/\/www.insee.fr\/fr\/statistiques\/1893198."},{"key":"10.1016\/j.bulcan.2026.05.006_bib0300","unstructured":"AVASTIN\u00ae (Bevacizumab) [Internet]. [cit\u00e9 27 janvier 2026]. Disponible sur\u00a0: https:\/\/www.omedit-idf.fr\/wp-content\/uploads\/veilleavastin052023-1.pdf."},{"key":"10.1016\/j.bulcan.2026.05.006_bib0305","unstructured":"R\u00e9f\u00e9rentiel glioblastome (grade IV OMS) [Internet]. ANOCEF 2018. 2023 [cit\u00e9 10 juillet 2023]. Disponible sur\u00a0: https:\/\/www.anocef.org\/."},{"key":"10.1016\/j.bulcan.2026.05.006_bib0310","unstructured":"Recommandations pour l\u2019administration des th\u00e9rapies syst\u00e9miques en neuro-oncologie adulte [Internet]. ANOCEF 2016. 2023 [cit\u00e9 13 juin 2023]. Disponible sur\u00a0: https:\/\/www.anocef.org\/."},{"issue":"9","key":"10.1016\/j.bulcan.2026.05.006_bib0315","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","article-title":"EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma","volume":"15","author":"Weller","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.05.006_bib0320","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2014.9.FOCUS14516","article-title":"Bevacizumab for glioblastoma: current indications, surgical implications, and future directions","volume":"37","author":"Castro","year":"2014","journal-title":"Neurosurg Focus"},{"issue":"8","key":"10.1016\/j.bulcan.2026.05.006_bib0325","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1586\/14737175.2013.827414","article-title":"Bevacizumab for the treatment of glioblastoma","volume":"13","author":"Chowdhary","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.1016\/j.bulcan.2026.05.006_bib0330","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/PPO.0000000000000326","article-title":"Bevacizumab and glioblastoma: past, present, and future directions","volume":"24","author":"Kim","year":"2018","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.bulcan.2026.05.006_bib0335","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2011.0037","article-title":"Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis","volume":"9","author":"Wong","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.bulcan.2026.05.006_bib0340","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11060-017-2477-x","article-title":"The role of bevacizumab in the treatment of glioblastoma","volume":"133","author":"Diaz","year":"2017","journal-title":"J Neurooncol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.05.006_bib0345","first-page":"2049","article-title":"Bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2026.05.006_bib0350","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.bulcan.2026.05.006_bib0355","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.05.006_bib0360","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab versus bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.05.006_bib0365","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S1470-2045(18)30362-0","article-title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial","volume":"19","author":"Van den Bent","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0370","doi-asserted-by":"crossref","first-page":"103540","DOI":"10.1016\/j.critrevonc.2021.103540","article-title":"The current landscape of systemic therapy for recurrent glioblastoma: a systematic review of randomized-controlled trials","volume":"169","author":"Fazzari","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.05.006_bib0375","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0380","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Protocol for Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2026.05.006_bib0385","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/neuonc\/now046","article-title":"Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio","volume":"18","author":"Chinot","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.05.006_bib0390","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00435979","article-title":"The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires","volume":"5","author":"Osoba","year":"1996","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.bulcan.2026.05.006_bib0395","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/neuonc\/noab011","article-title":"Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG\/RTOG 0825)","volume":"23","author":"Wefel","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.05.006_bib0400","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1148\/radiol.2020200978","article-title":"Noninvasive characterization of tumor angiogenesis and oxygenation in bevacizumab-treated recurrent glioblastoma by using dynamic susceptibility MRI: secondary analysis of the European Organization for research and treatment of cancer 26101 trial","volume":"297","author":"Kickingereder","year":"2020","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.bulcan.2026.05.006_bib0405","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/neuonc\/noaa120","article-title":"Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial","volume":"22","author":"Schell","year":"2020","journal-title":"Neuro Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.05.006_bib0410","first-page":"6480","article-title":"Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.bulcan.2026.05.006_bib0415","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/07357907.2023.2174261","article-title":"Efficacy and safety of bevacizumab for treating glioblastoma: a systematic review and meta-analysis of phase II and III randomized controlled trials","volume":"41","author":"Xie","year":"2023","journal-title":"Cancer Invest"},{"issue":"1","key":"10.1016\/j.bulcan.2026.05.006_bib0420","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","article-title":"Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2026.05.006_bib0425","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/2772432817666220517163609","article-title":"Efficacy of anti-VEGF drugs based combination therapies in recurrent glioblastoma: systematic review and meta-analysis","volume":"19","author":"Solipuram","year":"2024","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.05.006_bib0430","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/neuonc\/nov300","article-title":"Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy","volume":"18","author":"Saran","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0435","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jocn.2024.01.018","article-title":"Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: a retrospective clinical study","volume":"120","author":"Liao","year":"2024","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.bulcan.2026.05.006_bib0440","doi-asserted-by":"crossref","first-page":"106239","DOI":"10.1016\/j.clineuro.2020.106239","article-title":"Reduced-dose bevacizumab versus standard-dose bevacizumab in recurrent high-grade glioma: which one is better? A meta-analysis","volume":"198","author":"Chen","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2026.05.006_bib0445","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/jco.2009.27.15_suppl.2011","article-title":"RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)","volume":"27","author":"Gilbert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.05.006_bib0450","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/neuonc\/nov320","article-title":"Predicting glioblastoma response to bevacizumab through marker profiling?","volume":"18","author":"Kessler","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.05.006_bib0455","first-page":"86","article-title":"Biomarkers predicting tumor response and evasion to anti-angiogenic therapy","volume":"1825","author":"Jahangiri","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1016\/j.bulcan.2026.05.006_bib0460","first-page":"e29269","article-title":"Bevacizumab-induced hypertension as a potential physiological clinical biomarker for improved outcomes in patients with recurrent glioblastoma multiforme: a systematic review","volume":"14","author":"Khan","year":"2022","journal-title":"Cureus"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:18:08Z","timestamp":1789741088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0007455126003231"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.05.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of bevacizumab to treat glioblastoma in France: Regional practices in PACA and Corsica show a real therapeutic need","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}